Curis Lifesciences (NSE:CURIS) ROIC %: 16.06% (As of Mar. 2026)


NSE:CURIS Curis Lifesciences Ltd NSE:CURIS
31 GF Score
Price ₹100.70
! 2 Warning Signs
View Full Analysis

What is Curis Lifesciences ROIC %?

Curis Lifesciences NSE:CURIS 31 ROIC % is 16.06% as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Curis Lifesciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 16.06%.

As of today (2026-07-13), Curis Lifesciences's WACC % is 11.42%. Curis Lifesciences's ROIC % is 16.06% (calculated using TTM income statement data). Curis Lifesciences generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Curis Lifesciences  (NSE:CURIS) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Curis Lifesciences's WACC % is 11.42%. Curis Lifesciences's ROIC % is 16.06% (calculated using TTM income statement data). Curis Lifesciences generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.

Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Curis Lifesciences ROIC % Related Terms

Curis Lifesciences ROIC % Historical Data

* Premium members only.

The historical data trend for Curis Lifesciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences ROIC % Chart

Curis Lifesciences Annual Data
Trend Mar23 Mar24 Mar25 Mar26
ROIC %
11.26 24.28 20.98 16.06

Curis Lifesciences Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
ROIC % 11.26 24.28 20.98 16.06

NSE:CURIS vs ZTS, UTHR: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curis Lifesciences ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Curis Lifesciences's ROIC % falls into.


NSE:CURIS
31GF Score
Curis Lifesciences Ltd NSE:CURIS
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Lifesciences ROIC % Calculation

Curis Lifesciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2026 is calculated as:

ROIC % (A: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2025 ) + Invested Capital (A: Mar. 2026 ))/ count )
=105.71 * ( 1 - 27.66% )/( (357.48 + 594.886)/ 2 )
=76.470614/476.183
=16.06 %

where

Invested Capital(A: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=425.347 - 64.831 - ( 3.036 - max(0, 175.771 - 312.926+3.036))
=357.48

Invested Capital(A: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=815.207 - 88.67 - ( 131.651 - max(0, 274.034 - 691.405+131.651))
=594.886

Curis Lifesciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=105.71 * ( 1 - 27.66% )/( (357.48 + 594.886)/ 2 )
=76.470614/476.183
=16.06 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=425.347 - 64.831 - ( 3.036 - max(0, 175.771 - 312.926+3.036))
=357.48

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=815.207 - 88.67 - ( 131.651 - max(0, 274.034 - 691.405+131.651))
=594.886

Note: The Operating Income data used here is one times the annual (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 16.06% mean?
Curis Lifesciences (NSE:CURIS) has a ROIC % of 16.06% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Curis Lifesciences and its competitors.
Is Curis Lifesciences' ROIC % too high?
Curis Lifesciences' current ROIC % is 16.06%. The Drug Manufacturers industry median ROIC % is 4.49. Curis Lifesciences' value of 16.06% is 258.1% above this industry median. Overall, Curis Lifesciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' ROIC % compare to ZTS and UTHR?
Curis Lifesciences' ROIC % of 16.06% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.49. Curis Lifesciences' value of 16.06% is 258.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.49, based on 990 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current ROIC % of 16.06% is 258.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current ROIC % is 16.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current ROIC % of 16.06%. The current ROIC % is 16.06% and 258.1% above the Drug Manufacturers industry median of 4.49. Curis Lifesciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current ROIC % is 16.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curis Lifesciences Business Description

Address PF-23, GIDC Sanand - II, Industrial Acme Pharma, Opposite Teva Pharma, Sanand, Ahmedabad, GJ, IND, 382110
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
31GF Score

Get the complete analysis for NSE:CURIS

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹100.70
Price